25 XP   0   0   10

Enlivex Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Enlivex together

PenkeI guess you are interested in Enlivex Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enlivex Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Enlivex Therapeutics Ltd

I send you an email if I find something interesting about Enlivex Therapeutics Ltd.

Quick analysis of Enlivex (30 sec.)










What can you expect buying and holding a share of Enlivex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.62
Expected worth in 1 year
$0.18
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
$-1.44
Return On Investment
-99.2%

For what price can you sell your share?

Current Price per Share
$1.45
Expected price per share
$1.15 - $3.37
How sure are you?
50%

1. Valuation of Enlivex (5 min.)




Live pricePrice per Share (EOD)

$1.45

Intrinsic Value Per Share

$-14.40 - $-3.15

Total Value Per Share

$-12.78 - $-1.54

2. Growth of Enlivex (5 min.)




Is Enlivex growing?

Current yearPrevious yearGrowGrow %
How rich?$30m$68.4m-$27.4m-67.1%

How much money is Enlivex making?

Current yearPrevious yearGrowGrow %
Making money-$7.3m-$7.7m$377.5k5.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Enlivex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#530 / 1010

Most Revenue
#972 / 1010

Most Profit
#501 / 1010

Most Efficient
#412 / 1010

What can you expect buying and holding a share of Enlivex? (5 min.)

Welcome investor! Enlivex's management wants to use your money to grow the business. In return you get a share of Enlivex.

What can you expect buying and holding a share of Enlivex?

First you should know what it really means to hold a share of Enlivex. And how you can make/lose money.

Speculation

The Price per Share of Enlivex is $1.45. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enlivex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enlivex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.62. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enlivex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.49-33.7%-0.39-26.6%-0.42-28.8%-0.26-17.7%-0.19-13.4%
Usd Book Value Change Per Share-0.47-32.2%-0.36-24.8%-0.38-26.1%0.053.8%0.032.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.47-32.2%-0.36-24.8%-0.38-26.1%0.053.8%0.032.3%
Usd Price Per Share2.70-2.64-4.57-7.90-5.30-
Price to Earnings Ratio-1.38--1.73--2.82--13.84--9.93-
Price-to-Total Gains Ratio-5.78--7.42--10.54--30.33--24.57-
Price to Book Ratio1.67-1.22-1.25-6.98-5.95-
Price-to-Total Gains Ratio-5.78--7.42--10.54--30.33--24.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.45
Number of shares689
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.360.05
Usd Total Gains Per Share-0.360.05
Gains per Quarter (689 shares)-247.8137.75
Gains per Year (689 shares)-991.23150.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-991-10010151141
20-1982-19920302292
30-2974-29830453443
40-3965-39740604594
50-4956-49650755745
60-5947-59560906896
70-6939-6947010571047
80-7930-7938012081198
90-8921-8929013591349
100-9912-9920015101500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.043.033.01.3%
Book Value Change Per Share0.04.00.00.0%1.09.02.08.3%4.011.05.020.0%7.026.07.017.5%19.049.09.024.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.077.00.0%
Total Gains per Share0.04.00.00.0%1.09.02.08.3%4.011.05.020.0%7.026.07.017.5%19.049.09.024.7%

Fundamentals of Enlivex

About Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Fundamental data was last updated by Penke on 2024-04-11 06:54:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Enlivex Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Enlivex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Enlivex to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-25.8%+25.8%
5Y-25.8%10Y-12.9%-12.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y-25.8%-436.8%+411.0%
10Y-12.9%-597.3%+584.4%
1.1.2. Return on Assets

Shows how efficient Enlivex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enlivex to the Biotechnology industry mean.
  • -24.7% Return on Assets means that Enlivex generated $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enlivex Therapeutics Ltd:

  • The MRQ is -24.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.7%TTM-15.7%-9.0%
TTM-15.7%YOY-10.2%-5.6%
TTM-15.7%5Y-11.4%-4.3%
5Y-11.4%10Y-15.6%+4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.7%-13.3%-11.4%
TTM-15.7%-12.8%-2.9%
YOY-10.2%-11.6%+1.4%
5Y-11.4%-13.8%+2.4%
10Y-15.6%-15.6%+0.0%
1.1.3. Return on Equity

Shows how efficient Enlivex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enlivex to the Biotechnology industry mean.
  • -30.2% Return on Equity means Enlivex generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enlivex Therapeutics Ltd:

  • The MRQ is -30.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.2%TTM-19.0%-11.2%
TTM-19.0%YOY-11.6%-7.4%
TTM-19.0%5Y-14.1%-4.9%
5Y-14.1%10Y-18.4%+4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.2%-16.9%-13.3%
TTM-19.0%-16.1%-2.9%
YOY-11.6%-14.9%+3.3%
5Y-14.1%-19.3%+5.2%
10Y-18.4%-20.1%+1.7%

1.2. Operating Efficiency of Enlivex Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Enlivex is operating .

  • Measures how much profit Enlivex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enlivex to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-17.2%+17.2%
5Y-17.2%10Y-8.6%-8.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y-17.2%-486.2%+469.0%
10Y-8.6%-628.4%+619.8%
1.2.2. Operating Ratio

Measures how efficient Enlivex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.162-0.162
5Y0.16210Y0.081+0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y0.1625.679-5.517
10Y0.0817.823-7.742

1.3. Liquidity of Enlivex Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Enlivex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.57 means the company has $5.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 5.571. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.492. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.571TTM6.492-0.922
TTM6.492YOY13.690-7.198
TTM6.4925Y9.594-3.102
5Y9.59410Y9.976-0.382
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5713.863+1.708
TTM6.4924.169+2.323
YOY13.6905.337+8.353
5Y9.5946.122+3.472
10Y9.9766.434+3.542
1.3.2. Quick Ratio

Measures if Enlivex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enlivex to the Biotechnology industry mean.
  • A Quick Ratio of 8.90 means the company can pay off $8.90 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 8.900. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.290. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.900TTM11.290-2.390
TTM11.290YOY18.886-7.597
TTM11.2905Y15.014-3.725
5Y15.01410Y11.059+3.955
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.9003.504+5.396
TTM11.2903.991+7.299
YOY18.8865.371+13.515
5Y15.0146.088+8.926
10Y11.0596.395+4.664

1.4. Solvency of Enlivex Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Enlivex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enlivex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Enlivex assets are financed with 18.3% credit (debt) and the remaining percentage (100% - 18.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.183. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.170. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.183TTM0.170+0.014
TTM0.170YOY0.127+0.043
TTM0.1705Y0.168+0.001
5Y0.16810Y0.138+0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1830.339-0.156
TTM0.1700.337-0.167
YOY0.1270.271-0.144
5Y0.1680.368-0.200
10Y0.1380.388-0.250
1.4.2. Debt to Equity Ratio

Measures if Enlivex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enlivex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 22.4% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enlivex Therapeutics Ltd:

  • The MRQ is 0.224. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.204. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.224TTM0.204+0.020
TTM0.204YOY0.146+0.059
TTM0.2045Y0.216-0.011
5Y0.21610Y0.170+0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2240.392-0.168
TTM0.2040.403-0.199
YOY0.1460.335-0.189
5Y0.2160.427-0.211
10Y0.1700.461-0.291

2. Market Valuation of Enlivex Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Enlivex generates.

  • Above 15 is considered overpriced but always compare Enlivex to the Biotechnology industry mean.
  • A PE ratio of -1.38 means the investor is paying $-1.38 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enlivex Therapeutics Ltd:

  • The EOD is -0.741. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.380. Based on the earnings, the company is expensive. -2
  • The TTM is -1.726. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.741MRQ-1.380+0.639
MRQ-1.380TTM-1.726+0.345
TTM-1.726YOY-2.819+1.093
TTM-1.7265Y-13.836+12.110
5Y-13.83610Y-9.931-3.905
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.741-2.300+1.559
MRQ-1.380-2.656+1.276
TTM-1.726-2.718+0.992
YOY-2.819-4.145+1.326
5Y-13.836-6.258-7.578
10Y-9.931-6.315-3.616
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enlivex Therapeutics Ltd:

  • The EOD is -1.340. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.494. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.104. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.340MRQ-2.494+1.155
MRQ-2.494TTM-2.104-0.391
TTM-2.104YOY-2.520+0.417
TTM-2.1045Y-12.734+10.631
5Y-12.73410Y-10.154-2.581
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.340-2.974+1.634
MRQ-2.494-3.306+0.812
TTM-2.104-3.508+1.404
YOY-2.520-5.613+3.093
5Y-12.734-8.378-4.356
10Y-10.154-8.873-1.281
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Enlivex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.67 means the investor is paying $1.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Enlivex Therapeutics Ltd:

  • The EOD is 0.896. Based on the equity, the company is cheap. +2
  • The MRQ is 1.669. Based on the equity, the company is underpriced. +1
  • The TTM is 1.217. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.896MRQ1.669-0.773
MRQ1.669TTM1.217+0.452
TTM1.217YOY1.247-0.030
TTM1.2175Y6.977-5.760
5Y6.97710Y5.954+1.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8961.914-1.018
MRQ1.6692.116-0.447
TTM1.2172.097-0.880
YOY1.2472.881-1.634
5Y6.9773.550+3.427
10Y5.9543.936+2.018
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Enlivex Therapeutics Ltd.

3.1. Institutions holding Enlivex Therapeutics Ltd

Institutions are holding 8.933% of the shares of Enlivex Therapeutics Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Renaissance Technologies Corp0.33380.00036208932005.434
2023-12-31Morgan Stanley - Brokerage Accounts0.23910444603040.6885
2023-09-30Citadel Advisors Llc0.2026037683-932-2.4136
2023-12-31Susquehanna International Group, LLP0.1501027925279250
2023-12-31Edmond de Rothschild Holding S.A.0.06990.00061300000
2023-12-31Geode Capital Management, LLC0.05601042000
2023-12-31Wells Fargo & Co0.053709993111112.5084
2023-12-31Citigroup Inc0.02540472447240
2023-12-31UBS Group AG0.0197036632973430.8696
2023-12-31Steward Partners Investment Advisory, LLC0.01610.0001300000
2023-12-31Barclays PLC0.00540100000
2023-12-31Advisor Group Holdings, Inc.0.0022040000
2023-12-31Bank of America Corp0.00140266-572-68.2578
2023-12-31JPMorgan Chase & Co0.00130237-963-80.25
2023-12-31Advisory Services Network, LLC0.0002043430
2023-12-31Qube Research & Technologies00100
2023-09-30Goldman Sachs Group Inc000-11297-100
2023-09-30SRS Capital Advisors Inc000-290-100
2023-12-31Susquehanna International Group Ltd000-12326-100
2023-09-30SIMPLEX TRADING, LLC000-12675-100
Total 1.17690.001218904+1225+0.6%

3.2. Funds holding Enlivex Therapeutics Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Dolphin 90/10 IL0.23380.03394348200
2023-12-31I.B.I Up to 3 Years 80/20 IL0.10750.06192000000
2023-12-31MTF TR TA-Growth0.10261.216819073186610.8444
2024-02-29Fidelity Nasdaq Composite Index0.0560.00021042000
2023-12-31Dolphin Flexible0.04960.3824922900
2023-12-31I.B.I 75/25 Noga !0.04030.0853750000
2023-12-31I.B.I 90/100.03090.0325575000
2023-12-31Psagot ETF TA-Growth0.02431.21664511561.257
2023-12-31I.B.I Government + 10% IL0.01610.0336300000
2023-12-31I.B.I Tracking Portfolio No 2 DiscountBk0.01480.0475275000
2023-12-31I.B.I Up to 3 Years 70/30 IL0.01480.0843275000
2023-12-31Harel HTF TA All-Share IL0.00820.19271526241.5979
2023-12-31Dolphin75/25 IL0.00320.009658700
Total 0.70213.3973130578+1946+1.5%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Enlivex Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.468-0.360-23%-0.379-19%0.055-953%0.033-1518%
Book Value Per Share--1.6182.201-27%3.678-56%2.402-33%1.558+4%
Current Ratio--5.5716.492-14%13.690-59%9.594-42%9.976-44%
Debt To Asset Ratio--0.1830.170+8%0.127+45%0.168+9%0.138+33%
Debt To Equity Ratio--0.2240.204+10%0.146+54%0.216+4%0.170+32%
Dividend Per Share----0%-0%-0%-0%
Eps---0.489-0.385-21%-0.418-15%-0.257-47%-0.194-60%
Free Cash Flow Per Share---0.271-0.316+17%-0.477+76%-0.279+3%-0.197-27%
Free Cash Flow To Equity Per Share---0.271-0.311+15%-0.475+76%-0.210-22%-0.084-69%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---3.154--------
Intrinsic Value_10Y_min---14.398--------
Intrinsic Value_1Y_max---0.721--------
Intrinsic Value_1Y_min---1.473--------
Intrinsic Value_3Y_max---1.857--------
Intrinsic Value_3Y_min---4.425--------
Intrinsic Value_5Y_max---2.622--------
Intrinsic Value_5Y_min---7.355--------
Market Cap26967970.000-86%50216220.00049039858.550+2%85079295.700-41%146999614.680-66%98605127.550-49%
Net Profit Margin----0%-0%-0.2580%-0.1290%
Operating Margin----0%-0%-0.1720%-0.0860%
Operating Ratio----0%-0%0.162-100%0.081-100%
Pb Ratio0.896-86%1.6691.217+37%1.247+34%6.977-76%5.954-72%
Pe Ratio-0.741+46%-1.380-1.726+25%-2.819+104%-13.836+902%-9.931+619%
Price Per Share1.450-86%2.7002.637+2%4.575-41%7.904-66%5.302-49%
Price To Free Cash Flow Ratio-1.340+46%-2.494-2.104-16%-2.520+1%-12.734+411%-10.154+307%
Price To Total Gains Ratio-3.102+46%-5.775-7.424+29%-10.543+83%-30.330+425%-24.568+325%
Quick Ratio--8.90011.290-21%18.886-53%15.014-41%11.059-20%
Return On Assets---0.247-0.157-36%-0.102-59%-0.114-54%-0.156-37%
Return On Equity---0.302-0.190-37%-0.116-61%-0.141-53%-0.184-39%
Total Gains Per Share---0.468-0.360-23%-0.379-19%0.055-953%0.033-1518%
Usd Book Value--30084000.00040943000.000-27%68410000.000-56%44675600.000-33%28979300.000+4%
Usd Book Value Change Per Share---0.468-0.360-23%-0.379-19%0.055-953%0.033-1518%
Usd Book Value Per Share--1.6182.201-27%3.678-56%2.402-33%1.558+4%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.489-0.385-21%-0.418-15%-0.257-47%-0.194-60%
Usd Free Cash Flow---5032748.300-5876937.075+17%-8869500.000+76%-5186537.415+3%-3663818.708-27%
Usd Free Cash Flow Per Share---0.271-0.316+17%-0.477+76%-0.279+3%-0.197-27%
Usd Free Cash Flow To Equity Per Share---0.271-0.311+15%-0.475+76%-0.210-22%-0.084-69%
Usd Market Cap26967970.000-86%50216220.00049039858.550+2%85079295.700-41%146999614.680-66%98605127.550-49%
Usd Price Per Share1.450-86%2.7002.637+2%4.575-41%7.904-66%5.302-49%
Usd Profit---9095000.000-7375750.000-19%-7753250.000-15%-5038250.000-45%-3722650.000-59%
Usd Revenue----0%-0%227700.000-100%113850.000-100%
Usd Total Gains Per Share---0.468-0.360-23%-0.379-19%0.055-953%0.033-1518%
 EOD+3 -5MRQTTM+10 -19YOY+7 -225Y+7 -2410Y+7 -24

4.2. Fundamental Score

Let's check the fundamental score of Enlivex Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.741
Price to Book Ratio (EOD)Between0-10.896
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.900
Current Ratio (MRQ)Greater than15.571
Debt to Asset Ratio (MRQ)Less than10.183
Debt to Equity Ratio (MRQ)Less than10.224
Return on Equity (MRQ)Greater than0.15-0.302
Return on Assets (MRQ)Greater than0.05-0.247
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Enlivex Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.748
Ma 20Greater thanMa 502.598
Ma 50Greater thanMa 1003.181
Ma 100Greater thanMa 2002.856
OpenGreater thanClose1.450
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets36,831
Total Liabilities6,747
Total Stockholder Equity30,084
 As reported
Total Liabilities 6,747
Total Stockholder Equity+ 30,084
Total Assets = 36,831

Assets

Total Assets36,831
Total Current Assets33,764
Long-term Assets3,067
Total Current Assets
Cash And Cash Equivalents 926
Short-term Investments 26,507
Other Current Assets 6,331
Total Current Assets  (as reported)33,764
Total Current Assets  (calculated)33,764
+/-0
Long-term Assets
Property Plant Equipment 2,580
Long-term Assets Other 179
Long-term Assets  (as reported)3,067
Long-term Assets  (calculated)2,759
+/- 308

Liabilities & Shareholders' Equity

Total Current Liabilities6,061
Long-term Liabilities686
Total Stockholder Equity30,084
Total Current Liabilities
Short-term Debt 346
Accounts payable 827
Other Current Liabilities 4,888
Total Current Liabilities  (as reported)6,061
Total Current Liabilities  (calculated)6,061
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)686
Long-term Liabilities  (calculated)0
+/- 686
Total Stockholder Equity
Common Stock2,137
Retained Earnings -112,093
Accumulated Other Comprehensive Income 1,101
Other Stockholders Equity 138,939
Total Stockholder Equity (as reported)30,084
Total Stockholder Equity (calculated)30,084
+/-0
Other
Cash and Short Term Investments 27,433
Common Stock Shares Outstanding 18,599
Liabilities and Stockholders Equity 36,831
Net Debt 106
Net Working Capital 27,703
Short Long Term Debt Total 1,032



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
56,906
52,022
66,255
102,399
91,608
87,855
78,002
61,917
55,298
54,318
51,572
53,352
47,578
45,421
38,223
45,743
46,607
43,592
41,401
45,273
50,617
48,877
48,569
45,136
42,474
41,847
29,374
27,687
25,420
30,017
28,615
42,201
36,178
33,698
0
0
5,686
0
4,516
34,540
32,954
29,847
26,899
23,921
20,516
22,479
16,955
13,370
10,630
7,886
5,514
4,283
3,622
3,622
1,704
12,130
11,034
11,034
20,829
19,217
17,560
17,560
35,437
35,437
40,358
40,358
95,187
98,167
95,146
95,146
77,341
72,414
67,642
60,022
53,028
46,936
36,831
36,83146,93653,02860,02267,64272,41477,34195,14695,14698,16795,18740,35840,35835,43735,43717,56017,56019,21720,82911,03411,03412,1301,7043,6223,6224,2835,5147,88610,63013,37016,95522,47920,51623,92126,89929,84732,95434,5404,51605,6860033,69836,17842,20128,61530,01725,42027,68729,37441,84742,47445,13648,56948,87750,61745,27341,40143,59246,60745,74338,22345,42147,57853,35251,57254,31855,29861,91778,00287,85591,608102,39966,25552,02256,906
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,679
0
4,387
34,475
32,885
29,762
26,813
23,807
20,392
22,328
16,811
13,275
10,541
7,799
5,514
4,283
3,622
3,622
1,704
11,590
10,277
10,277
19,578
18,068
16,421
16,421
34,334
34,334
38,121
38,121
92,828
90,281
86,442
86,442
65,051
59,231
52,330
37,581
30,785
31,841
33,764
33,76431,84130,78537,58152,33059,23165,05186,44286,44290,28192,82838,12138,12134,33434,33416,42116,42118,06819,57810,27710,27711,5901,7043,6223,6224,2835,5147,79910,54113,27516,81122,32820,39223,80726,81329,76232,88534,4754,38705,679000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,550
0
4,243
34,128
10,583
7,011
9,122
4,947
7,286
9,526
8,714
5,923
6,871
4,100
5,163
4,105
3,526
3,526
1,674
11,351
9,736
9,736
14,548
5,448
3,948
3,948
10,163
10,163
5,673
5,673
12,612
22,146
11,202
11,202
20,151
38,552
47,822
13,138
3,458
1,971
926
9261,9713,45813,13847,82238,55220,15111,20211,20222,14612,6125,6735,67310,16310,1633,9483,9485,44814,5489,7369,73611,3511,6743,5263,5264,1055,1634,1006,8715,9238,7149,5267,2864,9479,1227,01110,58334,1284,24305,550000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40
40
40
41
8,017
8,060
8,060
20,043
20,043
30,034
30,034
77,988
65,484
72,928
72,928
42,334
299
299
22,839
25,443
28,527
26,507
26,50728,52725,44322,83929929942,33472,92872,92865,48477,98830,03430,03420,04320,0438,0608,0608,017414040400000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
129
0
144
347
274
676
585
734
1,060
722
1,093
332
663
682
342
178
28
28
30
161
213
213
2,751
2,445
2,403
2,403
751
751
1,164
1,164
1,345
1,777
2,199
2,199
2,453
1,463
647
1,604
1,884
1,343
0
01,3431,8841,6046471,4632,4532,1992,1991,7771,3451,1641,1647517512,4032,4032,4452,7512132131613028281783426826633321,0937221,0607345856762743471440129000000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
504
738
0
0
0
0
0
-1,164
-1,164
0
0
0
0
0
19,103
1,177
-1,491
0
-1,230
0
0-1,2300-1,4911,17719,10300000-1,164-1,16400000738504000000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
0
129
65
69
85
86
114
124
151
144
95
89
87
0
0
0
0
0
540
757
757
1,251
1,149
1,139
1,139
1,103
1,103
2,237
2,237
2,359
7,886
8,704
8,704
12,290
13,183
15,312
22,441
22,243
15,095
3,067
3,06715,09522,24322,44115,31213,18312,2908,7048,7047,8862,3592,2372,2371,1031,1031,1391,1391,1491,251757757540000008789951441511241148685696512907000000000000000000000000000000000000
       Property Plant Equipment 
1,772
2,433
6,163
5,622
5,607
5,427
5,100
4,662
4,335
4,205
3,866
3,591
3,022
2,697
2,111
1,859
1,694
1,603
1,463
1,485
1,540
1,445
1,288
1,218
1,126
1,164
1,146
1,023
919
916
802
1,403
2,081
2,392
0
0
2
0
30
55
60
74
75
81
91
93
88
84
71
68
0
0
388
0
0
469
685
685
758
675
1,058
1,058
696
1,038
2,140
2,140
2,265
7,573
8,219
8,219
11,886
12,761
14,900
14,791
14,308
14,299
2,580
2,58014,29914,30814,79114,90012,76111,8868,2198,2197,5732,2652,1402,1401,0386961,0581,058675758685685469003880068718488939181757460553002002,3922,0811,4038029169191,0231,1461,1641,1261,2181,2881,4451,5401,4851,4631,6031,6941,8592,1112,6973,0223,5913,8664,2054,3354,6625,1005,4275,6075,6226,1632,4331,772
       Goodwill 
0
0
0
0
0
0
0
0
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
33,377
33,409
33,409
25,537
25,537
25,537
14,882
14,882
14,882
15,103
15,103
15,103
15,103
15,103
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000015,10315,10315,10315,10315,10314,88214,88214,88225,53725,53725,53733,40933,40933,37731,27631,27631,27631,27631,27631,27631,27631,27631,27631,27631,27631,27600000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
00000000300000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
35,403
31,419
31,420
31,439
31,441
31,451
31,436
31,463
31,462
31,497
31,496
31,504
31,506
38,608
37,802
37,678
29,668
29,546
29,452
18,563
18,571
18,416
19,189
18,882
24,656
23,688
22,838
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
410
410
342
342
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000003423424104100000000000000000000000000022,83823,68824,65618,88219,18918,41618,57118,56329,45229,54629,66837,67837,80238,60831,50631,50431,49631,49731,46231,46331,43631,45131,44131,43931,42031,41935,4030000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
0
99
10
9
11
11
33
33
58
56
11
18
19
0
0
0
0
0
71
72
72
493
474
-329
-329
65
-277
97
97
94
313
482
482
118
139
412
104
7,935
512
179
1795127,935104412139118482482313949797-27765-329-329474493727271000001918115658333311119109905000000000000000000000000000000000000
> Total Liabilities 
14,607
4,485
4,498
6,060
5,869
11,146
10,633
9,180
11,381
7,066
7,148
14,712
11,982
15,304
13,100
18,166
19,443
12,529
11,422
10,029
13,180
11,712
9,420
9,272
8,766
8,487
8,381
7,525
7,077
7,748
8,503
14,110
11,398
11,908
0
0
131
0
715
1,146
2,280
1,752
1,768
1,813
2,584
2,300
1,468
1,999
1,931
1,618
792
537
460
460
144
1,222
1,328
1,328
5,468
5,434
6,278
6,278
5,245
5,245
4,871
4,871
4,981
10,084
10,107
10,107
8,855
9,140
10,801
9,448
8,693
8,157
6,747
6,7478,1578,6939,44810,8019,1408,85510,10710,10710,0844,9814,8714,8715,2455,2456,2786,2785,4345,4681,3281,3281,2221444604605377921,6181,9311,9991,4682,3002,5841,8131,7681,7522,2801,14671501310011,90811,39814,1108,5037,7487,0777,5258,3818,4878,7669,2729,42011,71213,18010,02911,42212,52919,44318,16613,10015,30411,98214,7127,1487,06611,3819,18010,63311,1465,8696,0604,4984,48514,607
   > Total Current Liabilities 
14,607
4,485
4,498
6,060
5,869
11,146
10,633
9,180
11,381
7,066
7,148
8,000
7,860
9,942
8,284
8,422
7,854
7,820
7,792
7,276
11,102
7,246
5,426
5,266
4,701
4,313
4,180
3,296
3,003
3,660
4,394
7,024
4,414
4,684
0
0
131
0
715
1,146
2,280
1,739
1,736
1,762
2,514
2,175
1,468
1,999
1,931
1,618
792
537
460
460
144
960
1,130
1,130
5,199
4,550
5,980
5,980
5,009
5,009
4,372
4,372
4,576
4,732
4,718
4,718
4,213
4,529
6,607
5,453
4,991
4,339
6,061
6,0614,3394,9915,4536,6074,5294,2134,7184,7184,7324,5764,3724,3725,0095,0095,9805,9804,5505,1991,1301,1309601444604605377921,6181,9311,9991,4682,1752,5141,7621,7361,7392,2801,1467150131004,6844,4147,0244,3943,6603,0033,2964,1804,3134,7015,2665,4267,24611,1027,2767,7927,8207,8548,4228,2849,9427,8608,0007,1487,06611,3819,18010,63311,1465,8696,0604,4984,48514,607
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
148
0
123
123
123
123
203
203
210
636
617
617
629
649
653
682
667
701
346
3467016676826536496296176176362102032031231231231230148159000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
148
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000148159000000000000000000000000000000000000000000000000000000000
       Accounts payable 
613
1,722
2,036
3,402
2,644
2,969
1,960
1,314
1,168
1,308
1,578
2,962
2,227
3,357
1,994
1,177
880
915
981
1,218
1,127
2,104
1,403
2,834
2,341
2,177
2,257
1,660
1,390
1,853
2,527
4,712
2,172
2,701
0
0
46
0
277
713
2,280
1,739
761
807
1,412
983
619
78
700
543
89
72
19
19
13
128
173
173
321
137
316
316
524
524
463
463
558
1,062
878
878
667
1,056
1,948
1,483
1,554
794
827
8277941,5541,4831,9481,0566678788781,0625584634635245243163161373211731731281319197289543700786199831,4128077611,7392,280713277046002,7012,1724,7122,5271,8531,3901,6602,2572,1772,3412,8341,4032,1041,1271,2189819158801,1771,9943,3572,2272,9621,5781,3081,1681,3141,9602,9692,6443,4022,0361,722613
       Other Current Liabilities 
13,994
2,763
2,462
2,658
3,225
8,177
8,673
7,866
10,213
5,758
5,570
5,038
5,633
6,585
6,290
7,245
6,974
6,905
6,811
6,058
7,362
4,624
3,358
1,618
1,884
1,747
1,534
1,247
1,224
1,319
1,379
1,824
1,754
1,594
0
0
85
0
438
433
995
0
975
955
1,102
1,192
849
1,921
1,231
1,075
703
465
441
441
131
832
957
957
4,878
4,413
5,541
5,541
4,362
4,362
3,706
3,706
3,808
3,034
3,223
3,223
2,917
2,824
4,006
3,288
2,770
2,844
4,888
4,8882,8442,7703,2884,0062,8242,9173,2233,2233,0343,8083,7063,7064,3624,3625,5415,5414,4134,8789579578321314414414657031,0751,2311,9218491,1921,1029559750995433438085001,5941,7541,8241,3791,3191,2241,2471,5341,7471,8841,6183,3584,6247,3626,0586,8116,9056,9747,2456,2906,5855,6335,0385,5705,75810,2137,8668,6738,1773,2252,6582,4622,76313,994
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
32
51
70
125
0
0
0
0
0
0
0
0
0
262
198
198
269
884
298
298
236
236
499
499
405
5,352
5,389
5,389
4,642
4,611
4,194
3,995
3,702
3,818
686
6863,8183,7023,9954,1944,6114,6425,3895,3895,3524054994992362362982988842691981982620000000001257051321300000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
242
130
5,106
3,874
2,641
1,409
365
349
373
356
334
310
286
261
232
206
183
160
3,089
2,934
3,116
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
0
0
7
6
611
7
637
0
256
0
0
499
449
405
5,352
5,389
5,226
4,642
4,611
0
0
0
0
0
000004,6114,6425,2265,3895,3524054494990025606377611670070000000000000000003,1162,9343,0891601832062322612863103343563733493651,4092,6413,8745,1061302420000000000000
> Total Stockholder Equity
32,320
37,138
48,201
96,339
85,739
76,709
67,369
52,737
43,917
47,252
44,424
38,640
35,596
30,117
25,123
27,577
27,164
31,063
29,979
35,244
37,437
37,165
39,149
35,864
33,708
33,360
20,993
20,162
18,343
22,269
20,112
28,091
24,780
21,790
0
0
5,555
0
3,801
33,394
30,674
28,095
25,131
22,108
17,932
20,179
15,487
11,371
8,699
6,268
4,722
3,746
3,162
3,162
1,560
10,908
9,706
9,706
15,361
13,783
11,282
11,282
30,192
30,192
35,487
35,487
90,206
88,083
85,039
85,039
68,486
63,274
56,841
50,574
44,335
38,779
30,084
30,08438,77944,33550,57456,84163,27468,48685,03985,03988,08390,20635,48735,48730,19230,19211,28211,28213,78315,3619,7069,70610,9081,5603,1623,1623,7464,7226,2688,69911,37115,48720,17917,93222,10825,13128,09530,67433,3943,80105,5550021,79024,78028,09120,11222,26918,34320,16220,99333,36033,70835,86439,14937,16537,43735,24429,97931,06327,16427,57725,12330,11735,59638,64044,42447,25243,91752,73767,36976,70985,73996,33948,20137,13832,320
   Common Stock
28
28
29
38
38
39
39
40
40
41
41
41
46
46
46
50
52
54
54
57
58
58
60
65
66
67
68
68
68
83
83
99
99
99
0
0
29
0
30
39
39
39
39
39
39
45
45
45
45
45
46
46
45
45
46
204
396
396
1,126
1,151
1,151
1,151
1,513
1,513
1,646
1,646
2,104
2,107
2,107
2,107
2,113
2,116
2,117
2,133
2,136
2,137
2,137
2,1372,1372,1362,1332,1172,1162,1132,1072,1072,1072,1041,6461,6461,5131,5131,1511,1511,1511,12639639620446454546464545454545393939393939300290099999983836868686766656058585754545250464646414141404039393838292828
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5
0
0
0
-22
0
0
0
-40
0
0
0
0
0
0
-3,832
-2,251
-2,251
-1,717
-1,367
-1,300
-1,300
-1,428
-1,428
977
977
244
1,101
1,101
1,101
1,101
1,101
1,101
1,101
1,101
1,101
1,101
1,1011,1011,1011,1011,1011,1011,1011,1011,1011,101244977977-1,428-1,428-1,300-1,300-1,367-1,717-2,251-2,251-3,832000000-40000-22000-50000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,053
27,326
33,262
36,367
36,805
37,104
59,333
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000059,33337,10436,80536,36733,26227,32627,0530000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,015-1,0150000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,926
0
6,930
38,626
39,062
39,777
40,499
41,027
41,702
48,515
47,508
48,062
48,503
48,704
48,790
48,885
48,871
48,871
48,962
29,240
27,326
27,326
36,367
36,805
37,104
37,104
59,615
59,615
70,361
70,361
131,663
132,104
133,796
133,796
135,375
135,893
136,648
137,583
138,133
138,539
138,939
138,939138,539138,133137,583136,648135,893135,375133,796133,796132,104131,66370,36170,36159,61559,61537,10437,10436,80536,36727,32627,32629,24048,96248,87148,87148,88548,79048,70448,50348,06247,50848,51541,70241,02740,49939,77739,06238,6266,93006,926000000000000000000000000000000000000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-835
Gross Profit-835-835
 
Operating Income (+$)
Gross Profit-835
Operating Expense-24,093
Operating Income-24,928-24,928
 
Operating Expense (+$)
Research Development17,987
Selling General Administrative6,243
Selling And Marketing Expenses0
Operating Expense24,09324,230
 
Net Interest Income (+$)
Interest Income0
Interest Expense-14
Other Finance Cost-14
Net Interest Income0
 
Pretax Income (+$)
Operating Income-24,928
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-29,068-20,788
EBIT - interestExpense = -24,942
-29,068
-29,054
Interest Expense14
Earnings Before Interest and Taxes (EBIT)-24,928-29,054
Earnings Before Interest and Taxes (EBITDA)-24,093
 
After tax Income (+$)
Income Before Tax-29,068
Tax Provision-0
Net Income From Continuing Ops-27,162-29,068
Net Income-29,068
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses24,928
Total Other Income/Expenses Net-4,1400
 

Technical Analysis of Enlivex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enlivex. The general trend of Enlivex is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enlivex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enlivex Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.5 < 2.78 < 3.37.

The bearish price targets are: 1.2 > 1.15.

Tweet this
Enlivex Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enlivex Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enlivex Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enlivex Therapeutics Ltd. The current macd is -0.63554331.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Enlivex price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Enlivex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Enlivex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Enlivex Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartEnlivex Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enlivex Therapeutics Ltd. The current adx is 36.83.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Enlivex shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Enlivex Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enlivex Therapeutics Ltd. The current sar is 3.13302041.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Enlivex Therapeutics Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enlivex Therapeutics Ltd. The current rsi is 30.75. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Enlivex Therapeutics Ltd Daily Relative Strength Index (RSI) ChartEnlivex Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enlivex Therapeutics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Enlivex price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Enlivex Therapeutics Ltd Daily Stochastic Oscillator ChartEnlivex Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enlivex Therapeutics Ltd. The current cci is -59.9987111.

Enlivex Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartEnlivex Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enlivex Therapeutics Ltd. The current cmo is -42.67901914.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Enlivex Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartEnlivex Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enlivex Therapeutics Ltd. The current willr is -90.19607843.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Enlivex Therapeutics Ltd Daily Williams %R ChartEnlivex Therapeutics Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enlivex Therapeutics Ltd. The current atr is 0.34405323.

Enlivex Therapeutics Ltd Daily Average True Range (ATR) ChartEnlivex Therapeutics Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enlivex Therapeutics Ltd. The current obv is -4,280,889.

Enlivex Therapeutics Ltd Daily On-Balance Volume (OBV) ChartEnlivex Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enlivex Therapeutics Ltd. The current mfi is 22.09.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Enlivex Therapeutics Ltd Daily Money Flow Index (MFI) ChartEnlivex Therapeutics Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enlivex Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Enlivex Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enlivex Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5030.748
Ma 20Greater thanMa 502.598
Ma 50Greater thanMa 1003.181
Ma 100Greater thanMa 2002.856
OpenGreater thanClose1.450
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Enlivex with someone you think should read this too:
  • Are you bullish or bearish on Enlivex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enlivex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enlivex Therapeutics Ltd

I send you an email if I find something interesting about Enlivex Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Enlivex Therapeutics Ltd.

Receive notifications about Enlivex Therapeutics Ltd in your mailbox!